DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The company is headquartered in Chatillon, Auvergne-Rhone-Alpes and currently employs 109 full-time employees. The company went IPO on 2012-03-29. The firm's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. The company dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The firm's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The firm operates one subsidiary DBV Technologies Inc. in the United States.
Follow-Up Questions
Dbv Technologies SA のCEOは誰ですか？
Mr. Daniel Tasse は Dbv Technologies SA の Chief Executive Officer で、2018 から在籍しています。
DBVTF の株価パフォーマンスは？
DBVTF の現在の価格は $0 で、最終取引日から 0% decreased 変動しました。
Dbv Technologies SA の主な事業テーマや業界は？
Dbv Technologies SA は Biotechnology 業界、セクターは Health Care に属しています。
